ATLAS ACS -2, TIMI 51 () randomized 15, patients with recent ACS to either twice-daily doses of either mg or 5mg of rivaroxaban. Oral anticoagulant metaanalysis · "Not so fast" - Prescrire (continuing ed journal) behind paywall; Predictable use of rivaroxaban in ACS with. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS - TIMI 46): a randomised, double-blind, phase II trial.
A Closer Look at the ATLAS Trial Results
Wiki ATLAS ACS TIMI - medfødt
Feedback close x '. Create account Log in. The primary end point is Thrombolysis in Myocardial Infarction clinically significant bleeding major, minor, or requiring medical attention. ATLAS ACS - TIMI 46 compared the safety and efficacy of rivaroxaban, an oral direct factor Xa inhibitor, to placebo in patients with acute coronary syndromes. Epub Aug link to original article PubMed; ATLAS ACS 2– TIMI Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, Burton P, Cohen. Based on the promising results of the recently published ATLAS ACS 2 TIMI 51 trial, Johnson Johnson has submitted a supplemental new drug application to the.